cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pyxis Oncology Inc
2 watching
Current Price
$1.63
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
53.12M
52-Week High
52-Week High
9.49
52-Week Low
52-Week Low
1.1
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization53.12M
icon52-Week High9.49
icon52-Week Low1.1
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Pyxis Oncology Inc do?
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company s antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Pyxis Oncology Inc make?
News & Events about Pyxis Oncology Inc.
Globe Newswire
8 months ago
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ...
Ticker Report
9 months ago
Pyxis Oncology, Inc. (NASDAQ:PYXS Get Rating) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 421,500 shares, a decline of 21.7% from the March 31st total of 538,500 shares. Approximately 2.1% of the shares ...
Globe Newswire
10 months ago
- Data highlight PYX-106s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced...
PR Newswire
10 months ago
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology PR Newswire NEWARK, Del. and NANJING, China, March 29, 2022 - Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106...
Frequently Asked Questions
Frequently Asked Questions
What is Pyxis Oncology Inc share price today?
plus_minus_icon
Can Indians buy Pyxis Oncology Inc shares?
plus_minus_icon
How can I buy Pyxis Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Pyxis Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Pyxis Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Pyxis Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Pyxis Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Pyxis Oncology Inc?
plus_minus_icon
What percentage is Pyxis Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Pyxis Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.63
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00